Single-cell RNA Sequencing Reveals Reduced Intercellular Adhesion Molecule Crosstalk Between Activated Hepatic Stellate Cells and Neutrophils Alleviating Liver Fibrosis in Hepatitis B Virus Transgenic Mice Post Menstrual Blood-derived Mesenchymal...

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2024 Jul 23

PMID 39040848

Authors

Lijun Chen

Yuqi Huang

Ning Zhang

Jingjing Qu

Yangxin Fang

Jiamin Fu

Yin Yuan

Qi Zhang

Hang Li

Zuoshi Wen

Li Yuan

Lu Chen

Zhenyu Xu

Yifei Li

Huadong Yan

Hiromi Izawa

Lanjuan Li

Charlie Xiang

Affiliations

Soon will be listed here.

Abstract

Liver fibrosis can cause hepatitis B virus (HBV)-associated hepatocellular carcinoma. Menstrual blood-derived mesenchymal stem cells (MenSCs) can ameliorate liver fibrosis through paracrine. Single-cell RNA sequencing (scRNA-seq) may be used to explore the roadmap of activated hepatic stellate cell (aHSC) inactivation to target liver fibrosis. This study established HBV transgenic (HBV-Tg) mouse model of carbon tetrachloride (CCl)-induced liver fibrosis and demonstrated that MenSCs migrated to the injured liver to improve serological indices and reduce fibrotic accumulation. RNA-bulk analysis revealed that MenSCs mediated extracellular matrix accumulation and cell adhesion. Liver parenchymal cells and nonparenchymal cells were identified by scRNA-seq in the control, CCl, and MenSC groups, revealing the heterogeneity of fibroblasts/HSCs. A CellChat analysis revealed that diminished intercellular adhesion molecule (ICAM) signaling is vital for MenSC therapy. Specifically, in aHSCs acted on / and / in neutrophils, causing decreased adhesion. The expression of , , and was higher in CCl group than in the control group and decreased after MenSC therapy in neutrophil clusters. The , , , and had high expression and may be potential targets in neutrophils. This study highlights interacting cells, corresponding molecules, and underlying targets for MenSCs in treating HBV-associated liver fibrosis.

Citing Articles

Targeting immune cellular populations and transcription factors: unraveling the therapeutic potential of JQF for NAFLD.

Zhou L, Zhao J, Ma K, Hao R, Yao C, Gou X Front Immunol. 2025; 15():1445924.

PMID: 39840059 PMC: 11746100. DOI: 10.3389/fimmu.2024.1445924.

Combination of rapamycin and adipose-derived mesenchymal stromal cells enhances therapeutic potential for osteoarthritis.

Veret D, Tejedor G, Perez E, Chomette A, Farno M, Ferreira-Lopez R Stem Cell Res Ther. 2025; 16(1):9.

PMID: 39815291 PMC: 11737215. DOI: 10.1186/s13287-024-04090-8.

Adipose-derived mesenchymal stem cells inhibit hepatic stellate cells activation to alleviate liver fibrosis via Hippo pathway.

Liu H, Huang H, Liu Y, Yang Y, Deng H, Wang X Stem Cell Res Ther. 2024; 15(1):378.

PMID: 39449061 PMC: 11515333. DOI: 10.1186/s13287-024-03988-7.

References

Shi M, Li Y, Xu R, Meng F, Yu S, Fu J . Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatol Int. 2021; 15(6):1431-1441. PMC: 8651584. DOI: 10.1007/s12072-021-10199-2. View

Huppert S, Schwartz R . Multiple Facets of Cellular Homeostasis and Regeneration of the Mammalian Liver. Annu Rev Physiol. 2022; 85:469-493. PMC: 9918695. DOI: 10.1146/annurev-physiol-032822-094134. View

Zisser A, Ipsen D, Tveden-Nyborg P . Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets?. Biomedicines. 2021; 9(4). PMC: 8066583. DOI: 10.3390/biomedicines9040365. View

Du J, Jiang Y, Liu X, Ji X, Xu B, Zhang Y . HGF Secreted by Menstrual Blood-Derived Endometrial Stem Cells Ameliorates Non-Alcoholic Fatty Liver Disease Through Downregulation of Hepatic Rnf186. Stem Cells. 2022; 41(2):153-168. DOI: 10.1093/stmcls/sxac091. View

Zhou J, Feng X, Zhu J, Feng B, Yao Q, Pan Q . Mesenchymal stem cell treatment restores liver macrophages homeostasis to alleviate mouse acute liver injury revealed by single-cell analysis. Pharmacol Res. 2022; 179:106229. DOI: 10.1016/j.phrs.2022.106229. View

Kisseleva T, Brenner D . Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2020; 18(3):151-166. DOI: 10.1038/s41575-020-00372-7. View

Bai Y, Yang F, Luo P, Xie L, Chen J, Guan Y . Single-cell transcriptomic dissection of the cellular and molecular events underlying the triclosan-induced liver fibrosis in mice. Mil Med Res. 2023; 10(1):7. PMC: 9945401. DOI: 10.1186/s40779-023-00441-3. View

Liu K, Wang F, Xu R . Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cell Mol Immunol. 2020; 18(1):38-44. PMC: 7852892. DOI: 10.1038/s41423-020-00560-0. View

Rosenthal S, Liu X, Ganguly S, Dhar D, Pasillas M, Ricciardelli E . Heterogeneity of HSCs in a Mouse Model of NASH. Hepatology. 2021; 74(2):667-685. PMC: 8346581. DOI: 10.1002/hep.31743. View

10.

Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M . Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021; 11(2):e297. PMC: 7839959. DOI: 10.1002/ctm2.297. View

11.

Bui T, Wiesolek H, Sumagin R . ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020; 108(3):787-799. PMC: 7977775. DOI: 10.1002/JLB.2MR0220-549R. View

12.

Nishio T, Koyama Y, Liu X, Rosenthal S, Yamamoto G, Fuji H . Immunotherapy-based targeting of MSLN activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. Proc Natl Acad Sci U S A. 2021; 118(29). PMC: 8307749. DOI: 10.1073/pnas.2101270118. View

13.

Jiang P, Jia H, Qian X, Tang T, Han Y, Zhang Z . Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-α in patients with chronic hepatitis B. Hepatology. 2023; 79(1):167-182. DOI: 10.1097/HEP.0000000000000524. View

14.

Fathi-Kazerooni M, Fattah-Ghazi S, Darzi M, Makarem J, Nasiri R, Salahshour F . Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. Stem Cell Res Ther. 2022; 13(1):96. PMC: 8899458. DOI: 10.1186/s13287-022-02771-w. View

15.

Harris M, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R . The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2003; 32(Database issue):D258-61. PMC: 308770. DOI: 10.1093/nar/gkh036. View

16.

Nishio T, Hu R, Koyama Y, Liang S, Rosenthal S, Yamamoto G . Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. J Hepatol. 2019; 71(3):573-585. DOI: 10.1016/j.jhep.2019.04.012. View

17.

Yang W, He H, Wang T, Su N, Zhang F, Jiang K . Single-Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell-Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice. Hepatology. 2021; 74(5):2774-2790. PMC: 8597108. DOI: 10.1002/hep.31987. View

18.

Krenkel O, Hundertmark J, Ritz T, Weiskirchen R, Tacke F . Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis. Cells. 2019; 8(5). PMC: 6562512. DOI: 10.3390/cells8050503. View

19.

Lin Y, Yan M, Bai Z, Xie Y, Ren L, Wei J . Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnology. 2022; 20(1):432. PMC: 9526331. DOI: 10.1186/s12951-022-01636-x. View

20.

Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita K, Itoh M, Kawashima S . From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2005; 34(Database issue):D354-7. PMC: 1347464. DOI: 10.1093/nar/gkj102. View